Sugi Predict

Sugi Predict / Compounds / SCHEMBL24918858

SCHEMBL24918858

SCHEMBL24918858

CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)CCC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@]1(C)CCC/C=C\CCC[C@@](C)(C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(C)=O)C(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)CC)NC1=O

nearest known ligand 0.52

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ KRAS P01116 6/20 0.52
▸ BCL2A1 Q16548 4/20 0.49
▸ MCL1 Q07820 3/20 0.49
▸ ESR1 P03372 3/20 0.49
▸ ESR2 Q92731 3/20 0.49
▸ MAFG O15525 1/20 0.49
▸ EIF4E P06730 2/20 0.46
▸ EIF4EBP1 Q13541 2/20 0.46
▸ HSP90AB1 P08238 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24919299 0.91 KRAS (0.47) KRASBCL2A1MCL1ESR1ESR2
SCHEMBL24918853 0.87 BCL2A1 (0.50) KRASBCL2A1MCL1ESR1ESR2
SCHEMBL20694605 0.85 ESR1 (0.52) KRASBCL2A1MCL1ESR1ESR2
SCHEMBL22803251 0.83 BCL2A1 (0.51) KRASBCL2A1MCL1ESR1ESR2
SCHEMBL22803116 0.79 MAFG (0.63) KRASBCL2A1MCL1ESR1ESR2
SCHEMBL29343923 0.76 MCL1 (0.45) KRASBCL2A1MCL1ESR1ESR2
SCHEMBL20694567 0.75 ESR1 (0.53) BCL2A1MCL1ESR1ESR2MAFG
SCHEMBL20694360 0.74 ESR1 (0.49) KRASBCL2A1MCL1ESR1ESR2
SCHEMBL20694606 0.74 ESR1 (0.51) KRASBCL2A1MCL1ESR1ESR2
SCHEMBL20694568 0.73 ESR1 (0.44) KRASBCL2A1MCL1ESR1ESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230028880-A1 CD38-BINDING AGENTS AND USES THEREOF KLEO PHARMACEUTICALS, INC. 2023-01-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230028880-A1 CD38-BINDING AGENTS AND USES THEREOF CD38, CD47, CD2 KRAS 307/4885BCL2A1 979/4885MCL1 43/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.